Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations

被引：107

作者：

Costa, Daniel B. ^{[1
]}

Schumer, Susan T. ^{[1
]}

Tenen, Daniel G. ^{[1
]}

Kobayashi, Susumu ^{[1
]}

机构：

[1] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Div Hematol Oncol, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 07期

关键词：

D O I：

10.1200/JCO.2007.14.9039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1182 / 1184

页数：4

共 7 条

[1] Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor - Mutant lung adenocarcinomas with acquired resistance to kinase inhibitors [J].

Balak, Marissa N. ;

Gong, Yixuan ;

Riely, Gregory J. ;

Somwar, Romel ;

Li, Allan R. ;

Zakowski, Maureen F. ;

Chiang, Anne ;

Yang, Guangli ;

Ouerfelli, Ouathek ;

Kris, Mark G. ;

Ladanyi, Marc ;

Miller, Vincent A. ;

Pao, William .

CLINICAL CANCER RESEARCH, 2006, 12 (21) :6494-6501

[2] Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types [J].

Baselga, J ;

Rischin, D ;

Ranson, M ;

Calvert, H ;

Raymond, E ;

Kieback, DG ;

Kaye, SB ;

Gianni, L ;

Harris, A ;

Bjork, T ;

Averbuch, SD ;

Feyereislova, A ;

Swaisland, H ;

Rojo, F ;

Albanell, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (21) :4292-4302

[3] Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib [J].

Cho, Byoung Chul ;

Im, Chong-Kun ;

Park, Moo-Suk ;

Kim, Se Kyu ;

Chang, Joon ;

Park, Jong Pil ;

Choi, Hye Jin ;

Kim, Yu Jin ;

Shin, Sang-Joon ;

Sohn, Joo Hyuk ;

Kim, Hoguen ;

Kim, Joo Hang .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18) :2528-2533

[4] BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations [J].

Costa, Daniel B. ;

Halmos, Balazs ;

Kumar, Amit ;

Schumer, Susan T. ;

Huberman, Mark S. ;

Boggon, Titus J. ;

Tenen, Daniel G. ;

Kobayashi, Susumu .

PLOS MEDICINE, 2007, 4 (10) :1669-1680

[5] MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling [J].

Engelman, Jeffrey A. ;

Zejnullahu, Kreshnik ;

Mitsudomi, Tetsuya ;

Song, Youngchul ;

Hyland, Courtney ;

Park, Joon Oh ;

Lindeman, Neal ;

Gale, Christopher-Michael ;

Zhao, Xiaojun ;

Christensen, James ;

Kosaka, Takayuki ;

Holmes, Alison J. ;

Rogers, Andrew M. ;

Cappuzzo, Federico ;

Mok, Tony ;

Lee, Charles ;

Johnson, Bruce E. ;

Cantley, Lewis C. ;

Janne, Pasi A. .

SCIENCE, 2007, 316 (5827) :1039-1043

[6] Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies [J].

Hidalgo, M ;

Siu, LL ;

Nemunaitis, J ;

Rizzo, J ;

Hammond, LA ;

Takimoto, C ;

Eckhardt, SG ;

Tolcher, A ;

Britten, CD ;

Denis, L ;

Ferrante, K ;

Von Hoff, DD ;

Silberman, S ;

Rowinsky, EK .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (13) :3267-3279

[7] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

← 1 →